Emergent Biosolutions Stock Price, News & Analysis (NYSE:EBS)

$49.96 +0.79 (+1.61 %)
(As of 02/19/2018 12:49 PM ET)
Previous Close$49.17
Today's Range$48.85 - $50.93
52-Week Range$27.94 - $51.25
Volume303,500 shs
Average Volume337,427 shs
Market Capitalization$2.47 billion
P/E Ratio29.56
Dividend YieldN/A
Beta1.28

About Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions logoEmergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSE:EBS
CUSIP29089Q10
Phone240-631-3200

Debt

Debt-to-Equity Ratio0.38%
Current Ratio7.37%
Quick Ratio6.46%

Price-To-Earnings

Trailing P/E Ratio29.5621301775148
Forward P/E Ratio27.76
P/E Growth1.07

Sales & Book Value

Annual Sales$488.78 million
Price / Sales5.05
Cash Flow$2.85 per share
Price / Cash17.50
Book Value$14.72 per share
Price / Book3.39

Profitability

Trailing EPS$1.69
Net Income$51.77 million
Net Margins15.60%
Return on Equity15.20%
Return on Assets9.67%

Miscellaneous

Employees1,098
Outstanding Shares49,400,000

Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions Inc (NYSE:EBS) announced its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.41 by $0.32. The biopharmaceutical company had revenue of $149.43 million for the quarter, compared to the consensus estimate of $124.55 million. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. Emergent Biosolutions's revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.56 EPS. View Emergent Biosolutions' Earnings History.

When will Emergent Biosolutions make its next earnings announcement?

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Emergent Biosolutions.

Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2018?

3 equities research analysts have issued twelve-month price targets for Emergent Biosolutions' shares. Their predictions range from $43.00 to $55.00. On average, they expect Emergent Biosolutions' share price to reach $50.33 in the next year. View Analyst Ratings for Emergent Biosolutions.

Who are some of Emergent Biosolutions' key competitors?

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the folowing people:

  • Fuad El-Hibri, Executive Chairman of the Board (Age 59)
  • Daniel J. Abdun-Nabi, President, Chief Executive Officer, Director (Age 57)
  • Robert G. Kramer Sr., Chief Financial Officer, Executive Vice President, Administration, Treasurer (Age 59)
  • Adam Havey, Executive Vice President - Business Operations (Age 46)
  • Ronald B. Richard, Lead Independent Director (Age 61)
  • Sue Bailey M.D., Independent Director (Age 73)
  • Zsolt Harsanyi Ph.D., Independent Director (Age 73)
  • Jerome M. Hauer Ph.D., Independent Director (Age 65)
  • George A. Joulwan USA, Independent Director (Age 77)

Who owns Emergent Biosolutions stock?

Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.15%), Standard Life Aberdeen plc (3.57%), Renaissance Technologies LLC (3.21%), Acadian Asset Management LLC (3.49%), Snyder Capital Management L P (2.52%) and Glenmede Trust Co. NA (1.99%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

Who sold Emergent Biosolutions stock? Who is selling Emergent Biosolutions stock?

Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Deutsche Bank AG, Wells Fargo & Company MN, Glenmede Trust Co. NA, BlackRock Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc. and Gotham Asset Management LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.

Who bought Emergent Biosolutions stock? Who is buying Emergent Biosolutions stock?

Emergent Biosolutions' stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Amundi Pioneer Asset Management Inc., OppenheimerFunds Inc., Fuller & Thaler Asset Management Inc., Snyder Capital Management L P, Rice Hall James & Associates LLC and Boston Advisors LLC. View Insider Buying and Selling for Emergent Biosolutions.

How do I buy Emergent Biosolutions stock?

Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of Emergent Biosolutions stock can currently be purchased for approximately $49.96.

How big of a company is Emergent Biosolutions?

Emergent Biosolutions has a market capitalization of $2.47 billion and generates $488.78 million in revenue each year. The biopharmaceutical company earns $51.77 million in net income (profit) each year or $1.69 on an earnings per share basis. Emergent Biosolutions employs 1,098 workers across the globe.

How can I contact Emergent Biosolutions?

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]


MarketBeat Community Rating for Emergent Biosolutions (EBS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Emergent Biosolutions (NYSE:EBS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.673.002.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $50.33$48.00$45.00$44.00
Price Target Upside: 0.96% downside0.97% upside11.25% upside45.94% upside

Emergent Biosolutions (NYSE:EBS) Consensus Price Target History

Price Target History for Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions (NYSE:EBS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$55.00LowView Rating Details
1/16/2018Chardan CapitalBoost Price TargetBuy$47.00 -> $53.00MediumView Rating Details
9/30/2017Wells Fargo & CoReiterated RatingOutperform$41.00 -> $43.00MediumView Rating Details
1/9/2017CowenReiterated RatingHoldN/AView Rating Details
8/5/2016JPMorgan Chase & Co.Lower Price TargetOverweight$45.00 -> $36.00N/AView Rating Details
6/28/2016Singular ResearchLower Price TargetBuy$44.00 -> $40.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Emergent Biosolutions (NYSE:EBS) Earnings History and Estimates Chart

Earnings by Quarter for Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions (NYSE EBS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018$0.64N/AView Earnings Details
11/2/2017Q3 2017$0.41$0.73$124.55 million$149.43 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.26$0.13$111.57 million$100.77 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.31$0.23$121.30 million$116.90 millionViewListenView Earnings Details
2/23/2017Q4 2016$0.48$0.74$120.45 million$151.66 millionViewListenView Earnings Details
11/7/2016Q3$0.26$0.58$112.30 million$142.91 millionViewListenView Earnings Details
8/4/2016Q2($0.17)($0.18)$111.20 million$101.49 millionViewListenView Earnings Details
5/5/2016Q1($0.07)$0.16$101.83 million$111.00 millionViewListenView Earnings Details
2/25/2016Q4$0.69$0.78$168.07 million$168.10 millionViewListenView Earnings Details
11/5/2015Q315$0.55$0.83$151.42 million$164.90 millionViewListenView Earnings Details
8/6/2015Q215$0.18$0.36$114.25 million$126.10 millionViewListenView Earnings Details
5/7/2015Q1($0.46)($0.50)$62.70 million$63.60 millionViewListenView Earnings Details
3/5/2015Q115$0.97$0.75$147.00 million$148.00 millionViewListenView Earnings Details
11/6/2014Q414$0.37$0.67$126.90 million$138.00 millionViewListenView Earnings Details
8/7/2014Q214$0.26$0.24$109.25 million$110.30 millionViewListenView Earnings Details
5/8/2014Q114($0.34)($0.40)$57.30 million$53.90 millionViewListenView Earnings Details
3/6/2014Q413$0.36$0.42$93.83 million$94.10 millionViewListenView Earnings Details
11/7/2013Q313$0.21$0.37$79.13 million$89.10 millionViewListenView Earnings Details
8/5/2013Q2 2013$0.21$0.29$75.73 million$82.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.14)($0.22)$46.17 million$43.10 millionViewListenView Earnings Details
3/7/2013Q4 2012$0.44$0.44$95.09 million$94.61 millionViewListenView Earnings Details
11/1/2012Q312$0.22$0.18$73.53 million$66.60 millionViewN/AView Earnings Details
8/2/2012$0.21$0.21ViewN/AView Earnings Details
5/3/2012($0.18)($0.19)ViewN/AView Earnings Details
3/8/2012$0.72$0.78ViewN/AView Earnings Details
11/3/2011($0.04)$0.04ViewN/AView Earnings Details
8/4/2011$0.33$0.40ViewN/AView Earnings Details
5/5/2011($0.52)($0.64)ViewN/AView Earnings Details
3/10/2011$0.67$0.76ViewN/AView Earnings Details
11/4/2010Q3 2010$0.53$0.41ViewN/AView Earnings Details
8/5/2010Q2 2010$0.26$0.31ViewN/AView Earnings Details
5/5/2010Q1 2010$0.17$0.08ViewN/AView Earnings Details
3/4/2010Q4 2009$0.05$0.13ViewN/AView Earnings Details
11/5/2009Q3 2009$0.06$0.03ViewN/AView Earnings Details
8/6/2009Q2 2009$0.30$0.55ViewN/AView Earnings Details
5/7/2009Q1 2009$0.15$0.35ViewN/AView Earnings Details
3/5/2009Q4 2008$0.06$0.05ViewN/AView Earnings Details
11/6/2008Q3 2008$0.17$0.34ViewN/AView Earnings Details
8/7/2008Q2 2008$0.19$0.06ViewN/AView Earnings Details
5/7/2008Q1 2008$0.27$0.24ViewN/AView Earnings Details
3/7/2008Q4 2007$0.87$0.93ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Emergent Biosolutions (NYSE:EBS) Earnings Estimates

Current Year EPS Consensus Estimate: $1.8 EPS
Next Year EPS Consensus Estimate: $2.12 EPS

Dividends

Dividend History for Emergent Biosolutions (NYSE:EBS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Emergent Biosolutions (NYSE EBS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.50%
Institutional Ownership Percentage: 78.23%
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions (NYSE EBS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Jerome M HauerDirectorSell5,152$50.91$262,288.3223,797View SEC Filing  
1/2/2018Daniel Abdun-NabiCEOSell21,906$47.91$1,049,516.46226,040View SEC Filing  
12/13/2017Daniel Abdun-NabiCEOSell20,000$45.99$919,800.00224,134View SEC Filing  
12/12/2017Ronald RichardDirectorSell23,681$45.02$1,066,118.6247,091View SEC Filing  
12/7/2017Zsolt HarsanyiDirectorSell7,000$42.47$297,290.0037,077View SEC Filing  
11/29/2017Fuad El-HibriChairmanSell47,983$41.88$2,009,528.041,550,216View SEC Filing  
11/14/2017Fuad El-HibriChairmanSell40,000$40.37$1,614,800.00View SEC Filing  
11/7/2017George A JoulwanDirectorSell14,251$41.24$587,711.2434,323View SEC Filing  
11/3/2017Daniel Abdun-NabiCEOSell31,508$42.77$1,347,597.16215,642View SEC Filing  
9/29/2017Fuad El-HibriChairmanSell25,000$40.50$1,012,500.001,555,216View SEC Filing  
9/28/2017Ronald RichardDirectorSell22,415$40.00$896,600.0024,676View SEC Filing  
9/27/2017Adam HaveyEVPSell7,885$39.50$311,457.5033,931View SEC Filing  
9/27/2017Daniel Abdun-NabiCEOSell15,000$39.92$598,800.00219,134View SEC Filing  
9/27/2017Fuad El-HibriChairmanSell25,000$39.50$987,500.001,555,216View SEC Filing  
9/27/2017Ronald RichardDirectorSell1,266$40.00$50,640.0024,676View SEC Filing  
9/14/2017Fuad El-HibriChairmanSell25,000$38.50$962,500.001,603,763View SEC Filing  
9/8/2017Adam HaveyEVPSell7,885$37.06$292,218.1033,931View SEC Filing  
9/7/2017Fuad El-HibriChairmanSell16,439$37.50$616,462.501,605,216View SEC Filing  
9/5/2017Fuad El-HibriChairmanSell3,100$37.50$116,250.001,621,655View SEC Filing  
8/31/2017Daniel Abdun-NabiCEOSell15,000$37.21$558,150.00219,134View SEC Filing  
8/31/2017Fuad El-HibriChairmanSell5,461$37.50$204,787.501,624,755View SEC Filing  
8/15/2017Jerome M HauerDirectorSell10,776$35.83$386,104.0829,421View SEC Filing  
7/27/2017Fuad El-HibriChairmanSell25,000$36.50$912,500.001,630,216View SEC Filing  
7/20/2017Fuad El-HibriChairmanSell25,000$35.50$887,500.001,655,216View SEC Filing  
4/3/2017Adam HaveyEVPSell11,419$28.62$326,811.7826,046View SEC Filing  
3/8/2017Jerome M HauerDirectorSell2,576$31.27$80,551.5217,404View SEC Filing  
1/17/2017Adam HaveyEVPSell8,438$29.75$251,030.5041,424View SEC Filing  
1/17/2017Sue BaileyDirectorSell19,424$29.78$578,446.7234,637View SEC Filing  
1/10/2017Daniel Abdun-NabiInsiderSell28,240$31.28$883,347.20172,945View SEC Filing  
12/13/2016Ronald RichardDirectorSell5,900$34.09$201,131.0019,870View SEC Filing  
6/6/2016George A JoulwanDirectorSell4,700$44.12$207,364.0020,785View SEC Filing  
6/1/2016Daniel Abdun-NabiCEOSell8,699$43.74$380,494.26170,966View SEC Filing  
5/27/2016Fuad El-HibriMajor ShareholderSell9,835$43.50$427,822.501,649,073View SEC Filing  
5/26/2016Fuad El-HibriMajor ShareholderSell39,759$43.13$1,714,805.671,698,667View SEC Filing  
5/25/2016Fuad El-HibriMajor ShareholderSell85,000$42.52$3,614,200.001,719,073View SEC Filing  
5/25/2016Zsolt HarsanyiDirectorSell27,867$42.33$1,179,610.1141,685View SEC Filing  
5/24/2016Fuad El-HibriChairmanSell20,000$42.26$845,200.001,719,073View SEC Filing  
5/23/2016Fuad El-HibriChairmanSell45,000$42.62$1,917,900.001,719,073View SEC Filing  
5/20/2016Daniel Abdun-NabiCEOSell8,701$42.00$365,442.00179,665View SEC Filing  
5/19/2016Jerome M HauerDirectorSell3,134$41.22$129,183.4820,085View SEC Filing  
5/13/2016Louis W SullivanDirectorSell47,631$39.21$1,867,611.5128,800View SEC Filing  
5/12/2016Fuad El-HibriMajor ShareholderSell25,000$38.71$967,750.001,699,073View SEC Filing  
5/12/2016Jerome M HauerDirectorSell4,700$38.50$180,950.0018,800View SEC Filing  
5/11/2016Louis W SullivanDirectorSell9,969$39.25$391,283.2538,469View SEC Filing  
4/22/2016Fuad El-HibriMajor ShareholderSell4,209$40.50$170,464.501,724,073View SEC Filing  
4/18/2016Daniel Abdun-NabiCEOSell8,702$40.17$349,559.34194,319View SEC Filing  
4/18/2016Fuad El-HibriMajor ShareholderSell20,791$40.50$842,035.501,728,282View SEC Filing  
4/6/2016Fuad El-HibriMajor ShareholderSell50,000$39.00$1,950,000.001,774,073View SEC Filing  
4/6/2016Robert KramerEVPSell21,786$38.90$847,475.4077,551View SEC Filing  
4/4/2016Robert KramerEVPSell21,788$36.90$803,977.2080,597View SEC Filing  
4/1/2016Robert KramerEVPSell43,572$35.56$1,549,420.3291,607View SEC Filing  
3/14/2016Adam HaveyEVPSell4,359$33.96$148,031.6439,163View SEC Filing  
3/14/2016Jerome M HauerDirectorSell2,350$33.88$79,618.0014,100View SEC Filing  
3/11/2016Adam HaveyEVPSell11,112$33.84$376,030.0854,254View SEC Filing  
3/11/2016Louis W SullivanDirectorSell14,879$34.03$506,332.3743,379View SEC Filing  
3/7/2016Marvin L WhiteDirectorSell33,134$35.42$1,173,606.2841,100View SEC Filing  
1/4/2016Sue BaileyDirectorSell11,520$38.79$446,860.8028,500View SEC Filing  
12/30/2015Ronald RichardDirectorSell21,600$40.00$864,000.0013,733View SEC Filing  
12/24/2015Daniel Abdun-NabiCEOSell63,209$39.06$2,468,943.54185,368View SEC Filing  
11/19/2015Fuad El-Hibrimajor shareholderSell17,871$37.50$670,162.501,852,284View SEC Filing  
11/13/2015Fuad El-Hibrimajor shareholderSell13,013$36.50$474,974.501,842,255View SEC Filing  
11/12/2015Barry LabingerEVPSell36,126$35.64$1,287,530.6428,558View SEC Filing  
11/9/2015Fuad El-Hibrimajor shareholderSell13,225$35.50$469,487.501,835,268View SEC Filing  
11/6/2015Fuad El-Hibrimajor shareholderSell13,450$34.50$464,025.001,828,493View SEC Filing  
11/3/2015Fuad El-Hibrimajor shareholderSell13,689$33.50$458,581.501,821,943View SEC Filing  
9/11/2015Sue BaileyDirectorSell6,080$32.37$196,809.6028,500View SEC Filing  
8/13/2015George A JoulwanDirectorSell7,200$34.72$249,984.00View SEC Filing  
7/20/2015Fuad El-HibriChairmanSell234$34.50$8,073.00View SEC Filing  
7/13/2015Ronald RichardDirectorSell4,922$34.00$167,348.00View SEC Filing  
6/29/2015Ronald RichardDirectorSell4,923$32.76$161,277.48View SEC Filing  
6/22/2015Fuad El-HibriMajor ShareholderSell74,564$32.60$2,430,786.40View SEC Filing  
6/16/2015Louis W SullivanDirectorSell13,457$31.33$421,607.81View SEC Filing  
6/15/2015Adam HaveyEVPSell36,298$31.55$1,145,201.90View SEC Filing  
6/15/2015Fuad El-HibriMajor ShareholderSell45,436$32.18$1,462,130.48View SEC Filing  
1/20/2015Fuad El-HibriMajor ShareholderSell15,325$27.67$424,042.75View SEC Filing  
12/26/2014Ronald RichardDirectorSell5,000$28.00$140,000.00View SEC Filing  
12/17/2014Ronald RichardDirectorSell5,000$27.00$135,000.00View SEC Filing  
12/11/2014Fuad El-HibriMajor ShareholderSell119,341$26.00$3,102,866.00View SEC Filing  
11/28/2014Fuad El-HibriMajor ShareholderSell34,577$25.00$864,425.00View SEC Filing  
11/25/2014Fuad El-HibriMajor ShareholderSell9,014$25.00$225,350.00View SEC Filing  
11/25/2014Zsolt HarsanyiDirectorSell8,000$24.82$198,560.00View SEC Filing  
11/12/2014Fuad El-HibriMajor ShareholderSell2,311$25.00$57,775.00View SEC Filing  
11/7/2014Robert KramerCFOSell2,625$24.00$63,000.00View SEC Filing  
4/16/2014Robert KramerCFOSell50,189$24.34$1,221,600.2662,183View SEC Filing  
3/12/2014Adam HaveyEVPSell11,562$27.50$317,955.0036,145View SEC Filing  
3/11/2014Adam HaveyEVPSell17,655$26.96$475,978.8036,920View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Emergent Biosolutions (NYSE EBS) News Headlines

Source:
DateHeadline
Heres how much Gaithersburgs Emergent BioSolutions execs will take home in cash bonusesHere's how much Gaithersburg's Emergent BioSolutions execs will take home in cash bonuses
www.bizjournals.com - February 16 at 5:12 PM
Heres how much Emergent BioSolutions execs will take home in cash bonusesHere's how much Emergent BioSolutions execs will take home in cash bonuses
www.bizjournals.com - February 15 at 5:14 PM
Emergent Biosolutions (EBS) Scheduled to Post Earnings on WednesdayEmergent Biosolutions (EBS) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:20 AM
Update in Lawsuit for Investors in NYSE: EBS Shares Against Emergent Biosolutions Inc. Announced by Shareholders FoundationUpdate in Lawsuit for Investors in NYSE: EBS Shares Against Emergent Biosolutions Inc. Announced by Shareholders Foundation
finance.yahoo.com - February 12 at 9:46 AM
Zacks Investment Research Lowers Emergent Biosolutions (EBS) to SellZacks Investment Research Lowers Emergent Biosolutions (EBS) to Sell
www.americanbankingnews.com - February 9 at 8:58 PM
 Analysts Expect Emergent Biosolutions Inc (EBS) Will Announce Quarterly Sales of $182.16 Million Analysts Expect Emergent Biosolutions Inc (EBS) Will Announce Quarterly Sales of $182.16 Million
www.americanbankingnews.com - February 6 at 6:48 AM
$0.60 Earnings Per Share Expected for Emergent Biosolutions Inc (EBS) This Quarter$0.60 Earnings Per Share Expected for Emergent Biosolutions Inc (EBS) This Quarter
www.americanbankingnews.com - February 4 at 11:34 AM
Head-To-Head Analysis: Histogenics (HSGX) and Emergent Biosolutions (EBS)Head-To-Head Analysis: Histogenics (HSGX) and Emergent Biosolutions (EBS)
www.americanbankingnews.com - February 4 at 5:16 AM
Contrasting GlaxoSmithKline (GSK) & Emergent Biosolutions (EBS)Contrasting GlaxoSmithKline (GSK) & Emergent Biosolutions (EBS)
www.americanbankingnews.com - January 28 at 5:14 PM
Emergent Biosolutions (EBS) Research Coverage Started at Goldman Sachs GroupEmergent Biosolutions (EBS) Research Coverage Started at Goldman Sachs Group
www.americanbankingnews.com - January 28 at 5:10 PM
Emergent Biosolutions Inc (EBS) Director Jerome M. Hauer Sells 5,152 SharesEmergent Biosolutions Inc (EBS) Director Jerome M. Hauer Sells 5,152 Shares
www.americanbankingnews.com - January 24 at 9:10 PM
Inovios Influenza Vaccine Shows Potential, Shares RallyInovio's Influenza Vaccine Shows Potential, Shares Rally
finance.yahoo.com - January 24 at 3:59 PM
Emergent Biosolutions Inc (EBS) Expected to Post Quarterly Sales of $182.16 MillionEmergent Biosolutions Inc (EBS) Expected to Post Quarterly Sales of $182.16 Million
www.americanbankingnews.com - January 20 at 2:32 PM
10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment
finance.yahoo.com - January 19 at 10:28 AM
Emergent Biosolutions (EBS) PT Raised to $53.00Emergent Biosolutions (EBS) PT Raised to $53.00
www.americanbankingnews.com - January 16 at 8:08 AM
Exact Sciences (EXAS) in Focus: Stock Moves 5.1% HigherExact Sciences (EXAS) in Focus: Stock Moves 5.1% Higher
finance.yahoo.com - January 10 at 9:28 AM
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and MedicinesThe Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
finance.yahoo.com - January 8 at 9:44 AM
Emergent Starts Phase II Study on Anti-influenza CandidateEmergent Starts Phase II Study on Anti-influenza Candidate
www.zacks.com - January 5 at 9:29 AM
Emergent Biosolutions Inc (EBS) Sees Large Decline in Short InterestEmergent Biosolutions Inc (EBS) Sees Large Decline in Short Interest
www.americanbankingnews.com - January 5 at 2:10 AM
Insider Selling: Emergent Biosolutions Inc (EBS) CEO Sells 21,906 Shares of StockInsider Selling: Emergent Biosolutions Inc (EBS) CEO Sells 21,906 Shares of Stock
www.americanbankingnews.com - January 4 at 7:30 PM
Emergent BioSolutions (EBS) Commences Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A InfectionEmergent BioSolutions (EBS) Commences Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
www.streetinsider.com - January 4 at 5:25 PM
Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A InfectionEmergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
finance.yahoo.com - January 4 at 9:22 AM
5 Reasons to Pick Emergent as an Investment-Worthy Stock5 Reasons to Pick Emergent as an Investment-Worthy Stock
finance.yahoo.com - January 3 at 8:35 AM
Emergent BioSolutions to Participate in First Quarter 2018 Investor ConferencesEmergent BioSolutions to Participate in First Quarter 2018 Investor Conferences
finance.yahoo.com - January 3 at 8:35 AM
$182.16 Million in Sales Expected for Emergent Biosolutions Inc (EBS) This Quarter$182.16 Million in Sales Expected for Emergent Biosolutions Inc (EBS) This Quarter
www.americanbankingnews.com - January 3 at 6:00 AM
New Strong Buy Stocks for January 2ndNew Strong Buy Stocks for January 2nd
www.zacks.com - January 2 at 9:22 AM
Emergent BioSolutions Inc. (EBS)Emergent BioSolutions Inc. (EBS)
finance.yahoo.com - January 1 at 5:18 PM
 Analysts Anticipate Emergent Biosolutions Inc (EBS) Will Announce Earnings of $0.59 Per Share Analysts Anticipate Emergent Biosolutions Inc (EBS) Will Announce Earnings of $0.59 Per Share
www.americanbankingnews.com - January 1 at 3:12 PM
Financial Analysis: Emergent Biosolutions (EBS) and Horizon Pharma (HZNP)Financial Analysis: Emergent Biosolutions (EBS) and Horizon Pharma (HZNP)
www.americanbankingnews.com - December 21 at 3:28 PM
2 Biotech Stocks with Month-Long Upward Estimate Revisions2 Biotech Stocks with Month-Long Upward Estimate Revisions
www.zacks.com - December 19 at 5:24 PM
Emergent Biosolutions (EBS) Lowered to "Hold" at Zacks Investment ResearchEmergent Biosolutions (EBS) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - December 19 at 11:52 AM
Should You Get Rid of Peregrine Pharmaceuticals (PPHM) Now?Should You Get Rid of Peregrine Pharmaceuticals (PPHM) Now?
www.zacks.com - December 18 at 9:36 AM
Sanofi/Alnylam Say FDA Lifts Clinical Hold on FitusiranSanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran
finance.yahoo.com - December 18 at 9:36 AM
 Brokerages Anticipate Emergent Biosolutions, Inc. (EBS) Will Post Quarterly Sales of $182.16 Million Brokerages Anticipate Emergent Biosolutions, Inc. (EBS) Will Post Quarterly Sales of $182.16 Million
www.americanbankingnews.com - December 17 at 3:38 AM
$0.62 EPS Expected for Emergent Biosolutions, Inc. (EBS) This Quarter$0.62 EPS Expected for Emergent Biosolutions, Inc. (EBS) This Quarter
www.americanbankingnews.com - December 15 at 9:30 PM
Insider Selling: Emergent Biosolutions, Inc. (EBS) CEO Sells 20,000 Shares of StockInsider Selling: Emergent Biosolutions, Inc. (EBS) CEO Sells 20,000 Shares of Stock
www.americanbankingnews.com - December 14 at 5:34 PM
Insider Selling: Emergent Biosolutions, Inc. (EBS) Director Sells 23,681 Shares of StockInsider Selling: Emergent Biosolutions, Inc. (EBS) Director Sells 23,681 Shares of Stock
www.americanbankingnews.com - December 13 at 11:22 AM
ETFs with exposure to Emergent BioSolutions, Inc. : December 12, 2017ETFs with exposure to Emergent BioSolutions, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 5:52 PM
Five Marvelous Momentum Stocks to Buy NowFive Marvelous Momentum Stocks to Buy Now
finance.yahoo.com - December 12 at 5:52 PM
Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian GovernmentEmergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
finance.yahoo.com - December 12 at 9:51 AM
Zsolt Harsanyi Sells 7,000 Shares of Emergent Biosolutions, Inc. (EBS) StockZsolt Harsanyi Sells 7,000 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - December 11 at 11:32 AM
New Strong Buy Stocks for December 1stNew Strong Buy Stocks for December 1st
finance.yahoo.com - December 1 at 4:46 PM
Insider Selling: Emergent Biosolutions, Inc. (EBS) Chairman Sells 47,983 Shares of StockInsider Selling: Emergent Biosolutions, Inc. (EBS) Chairman Sells 47,983 Shares of Stock
www.americanbankingnews.com - November 30 at 1:54 PM
Emergent BioSolutions to Host 2017 Analyst & Investor DayEmergent BioSolutions to Host 2017 Analyst & Investor Day
finance.yahoo.com - November 30 at 9:53 AM
Treichl Sees Central Banks Taking Over BitcoinTreichl Sees Central Banks Taking Over Bitcoin
finance.yahoo.com - November 30 at 9:53 AM
Emergent BioSolutions Larger Than S&P 500 Component Lennar CorporationEmergent BioSolutions Larger Than S&P 500 Component Lennar Corporation
www.nasdaq.com - November 29 at 9:22 AM
Emergent Biosolutions (EBS) Upgraded by Zacks Investment Research to "Strong-Buy"Emergent Biosolutions (EBS) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - November 28 at 10:36 AM
New Strong Buy Stocks for November 28thNew Strong Buy Stocks for November 28th
finance.yahoo.com - November 28 at 8:48 AM
Should You Buy Emergent BioSolutions Inc (EBS) At This PE Ratio?Should You Buy Emergent BioSolutions Inc (EBS) At This PE Ratio?
finance.yahoo.com - November 25 at 10:28 AM
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 23, 2017Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 23, 2017
finance.yahoo.com - November 23 at 4:18 PM

SEC Filings

Emergent Biosolutions (NYSE:EBS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Emergent Biosolutions (NYSE:EBS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Emergent Biosolutions (NYSE EBS) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.